Results 61 to 70 of about 805,395 (207)

Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period

Science, 2020
What happens next? Four months into the severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) outbreak, we still do not know enough about postrecovery immune protection and environmental and seasonal influences on transmission to predict ...
S. Kissler, C. Tedijanto, E. Goldstein, Y. Grad, M. Lipsitch   +4 more
semanticscholar   +1 more source

Susceptibility of lung cancer patients to COVID‐19: A review of the pandemic data from multiple nationalities

Thoracic Cancer, 2021
Several studies have highlighted that cancer patients tend to be more susceptible to develop severe infection and to die from COVID‐19. Certain medical conditions such as immunosuppression, presence of comorbidities, and underlying pulmonary damage are ...
Ana Emília Goulart Lemos, Gabriela Ribeiro Silva, Etel Rodrigues Pereira Gimba, Aline da Rocha Matos   +3 more
doaj   +1 more source

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

New England Journal of Medicine, 2020
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine.
L. Jackson, E. Anderson, N. Rouphael, P. Roberts, M. Makhene, R. Coler, M. P. McCullough, J. Chappell, M. Denison, Laura J. Stevens, A. Pruijssers, A. McDermott, B. Flach, N. Doria-Rose, Kizzmekia S. Corbett, Kaitlyn M. Morabito, S. O'dell, S. Schmidt, P. Swanson, M. Padilla, J. Mascola, K. Neuzil, H. Bennett, Wellington Sun, E. Peters, M. Makowski, J. Albert, Kaitlyn A. Cross, Wendy L. Buchanan, Rhonda Pikaart-Tautges, J. Ledgerwood, B. Graham, J. Beigel   +32 more
semanticscholar   +1 more source

Detection of a SARS-CoV-2 variant of concern in South Africa

Nature, 2021
Continued uncontrolled transmission of SARS-CoV-2 in many parts of the world is creating conditions for substantial evolutionary changes to the virus1,2.
H. Tegally, E. Wilkinson, M. Giovanetti, A. Iranzadeh, V. Fonseca, J. Giandhari, D. Doolabh, S. Pillay, E. J. San, N. Msomi, K. Mlisana, A. von Gottberg, S. Walaza, Mushal Allam, A. Ismail, T. Mohale, A. Glass, S. Engelbrecht, G. V. Van Zyl, W. Preiser, Francesco Petruccione, A. Sigal, D. Hardie, G. Marais, N. Hsiao, S. Korsman, M. Davies, L. Tyers, I. Mudau, Denis York, C. Maslo, D. Goedhals, S. Abrahams, O. Laguda-Akingba, A. Alisoltani-Dehkordi, A. Godzik, C. K. Wibmer, B. Sewell, J. Lourenço, L. Alcântara, S. K. Kosakovsky Pond, S. Weaver, D. Martin, R. Lessells, J. Bhiman, C. Williamson, Tulio de Oliveira   +46 more
semanticscholar   +1 more source

Inhibition of SARS‐CoV‐2‐mediated thromboinflammation by CLEC2.Fc

EMBO Molecular Medicine, 2023
Thromboinflammation is the major cause of morbidity and mortality in COVID‐19 patients, and post‐mortem examination demonstrates the presence of platelet‐rich thrombi and microangiopathy in visceral organs.
Pei‐Shan Sung, Cheng‐Pu Sun, Mi‐Hua Tao, Shie‐Liang Hsieh   +3 more
doaj   +1 more source

Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa

Nature, 2021
The SARS-CoV-2 epidemic in southern Africa has been characterized by three distinct waves. The first was associated with a mix of SARS-CoV-2 lineages, while the second and third waves were driven by the Beta (B.1.351) and Delta (B.1.617.2) variants ...
R. Viana, S. Moyo, D. Amoako, H. Tegally, C. Scheepers, C. Althaus, U. J. Anyaneji, P. Bester, M. F. Boni, M. Chand, W. Choga, R. Colquhoun, M. Davids, K. Deforche, D. Doolabh, L. du Plessis, S. Engelbrecht, J. Everatt, J. Giandhari, M. Giovanetti, D. Hardie, V. Hill, N. Hsiao, A. Iranzadeh, A. Ismail, Charity Joseph, R. Joseph, Legodile Koopile, S. K. Kosakovsky Pond, M. Kraemer, Lesego Kuate-Lere, O. Laguda-Akingba, Onalethatha Lesetedi-Mafoko, R. Lessells, S. Lockman, Alexander G. Lucaci, Arisha Maharaj, Boitshoko Mahlangu, Tongai Gibson Maponga, Kamela Mahlakwane, Z. Makatini, G. Marais, D. Maruapula, K. Masupu, M. Matshaba, S. Mayaphi, N. Mbhele, Mpaphi B. Mbulawa, A. Mendes, K. Mlisana, A. Mnguni, T. Mohale, M. Moir, Kgomotso Moruisi, M. Mosepele, Gerald Motsatsi, M. Motswaledi, T. Mphoyakgosi, N. Msomi, Peter N. Mwangi, Y. Naidoo, Noxolo N. Ntuli, M. Nyaga, Lucier Olubayo, S. Pillay, Botshelo Radibe, Yajna Ramphal, U. Ramphal, J. E. San, L. Scott, R. Shapiro, L. Singh, P. Smith-Lawrence, W. Stevens, A. Strydom, K. Subramoney, N. Tebeila, D. Tshiabuila, J. Tsui, Stephanie van Wyk, S. Weaver, C. K. Wibmer, E. Wilkinson, N. Wolter, A. Zarebski, Boitumelo J. L. Zuze, D. Goedhals, W. Preiser, F. Treurnicht, M. Venter, C. Williamson, O. Pybus, J. Bhiman, A. Glass, D. Martin, A. Rambaut, S. Gaseitsiwe, A. von Gottberg, Tulio de Oliveira   +98 more
semanticscholar   +1 more source

Whole genome sequencing of recombinant viruses obtained from co-infection and superinfection of Vero cells with modified vaccinia virus ankara vectored influenza vaccine and a naturally occurring cowpox virus

Frontiers in Immunology
Modified vaccinia virus Ankara (MVA) has been widely tested in clinical trials as recombinant vector vaccine against infectious diseases and cancers in humans and animals.
Diana Diaz-Cánova, Ugo Moens, Annika Brinkmann, Andreas Nitsche, Malachy Ifeanyi Okeke   +4 more
doaj   +1 more source

17β‐estradiol reduces SARS‐CoV‐2 infection in vitro

Physiological Reports, 2021
The COVID‐19 has originated from Wuhan, China, in December 2019 and has been affecting the public health system, society, and economy in an unheard‐of manner. There is no specific treatment or vaccine available for COVID‐19. Previous data showed that men
Robertha Mariana Rodrigues Lemes, Angelica Jardim Costa, Cynthia Silva Bartolomeo, Taysa Bervian Bassani, Michelle Sayuri Nishino, Gustavo Jose da Silva Pereira, Soraya Soubhi Smaili, Rui Monteiro de Barros Maciel, Carla Torres Braconi, Edgar Ferreira da Cruz, Ana Lopez Ramirez, Juliana Terzi Maricatto, Luiz Mario Ramos Janini, Carla Máximo Prado, Roberta Sessa Stilhano, Rodrigo Portes Ureshino   +15 more
doaj   +1 more source

Animal models for SARS‐CoV‐2 infection and pathology

MedComm, 2021
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is the etiology of coronavirus disease 2019 (COVID‐19) pandemic. Current variants including Alpha, Beta, Gamma, Delta, and Lambda increase the capacity of infection and transmission of SARS‐CoV‐
Zhenfei Bi, Weiqi Hong, Jingyun Yang, Shuaiyao Lu, Xiaozhong Peng   +4 more
doaj   +1 more source

Follow-up SARS-CoV-2 serological study of a health care worker cohort following COVID-19 booster vaccination

BMC Infectious Diseases
Background Studies have shown that Omicron breakthrough infections can occur at higher SARS-CoV-2 antibody levels compared to previous variants. Estimating the magnitude of immunological protection induced from COVID-19 vaccination and previous infection
Alexander Hönning, Sara Tomczyk, Julia Hermes, Marica Grossegesse, Natalie Hofmann, Janine Michel, Markus Neumann, Andreas Nitsche, Berthold Hoppe, Tim Eckmanns, Hajo Schmidt-Traub, Kristina Zappel   +11 more
doaj   +1 more source